Results 31 to 40 of about 494,085 (317)

Immune-mediated inflammation promotes subclinical atherosclerosis in recent-onset psoriatic arthritis patients without conventional cardiovascular risk factors [PDF]

, 2018
Studies on the inflammatory burden in recent-onset psoriatic arthritis (PsA) patients without conventional cardiovascular risk factors (CVRFs) are not available.
Capani, Francisco, Chiocconi, Monica, Cosentino, Vanesa Laura, Kerzberg, Eduardo Mario, Kogan, Nora, Kolliker Frers, Rodolfo Alberto, Otero-Losada, Matilde Estela, Tau, Julia, Urdapilleta, Adriana   +8 more
core   +1 more source

Clinical and Genetic Risk Factors Associated with Psoriatic Arthritis among Patients with Psoriasis. [PDF]

, 2018
IntroductionPsoriatic arthritis (PsA) is a chronic, inflammatory arthritis that affects an estimated 30% of patients with psoriasis. PsA is underdiagnosed in primary care and dermatology clinics due to a variety of reasons, including failure of ...
Ahn, Richard, Leslie, Stephen, Liao, Wilson, Yan, Di   +3 more
core   +3 more sources

Use of IL-23 Inhibitors for the Treatment of Plaque Psoriasis and Psoriatic Arthritis: A Comprehensive Review

American Journal of Clinical Dermatology, 2020
Psoriasis is a common inflammatory skin disease with multiple comorbidities, including psoriatic arthritis and coronary artery disease, that can severely impact an individual’s quality of life and daily functioning.
Kevin Yang, A. Oak, B. Elewski
semanticscholar   +1 more source

Special Article: 2018 American College of Rheumatology/National Psoriasis Foundation Guideline for the Treatment of Psoriatic Arthritis.

Arthritis care & research, 2019
OBJECTIVE To develop an evidence-based guideline for the pharmacologic and nonpharmacologic treatment of psoriatic arthritis (PsA), as a collaboration between the American College of Rheumatology (ACR) and the National Psoriasis Foundation (NPF ...
Jasvinder A. Singh, G. Guyatt, A. Ogdie, D. Gladman, C. Deal, A. Deodhar, M. Dubreuil, J. Dunham, M. E. Husni, Sarah Kenny, J. Kwan-Morley, Janice Lin, Paula Marchetta, Philip J Mease, J. F. Merola, Julie Miner, Christopher T. Ritchlin, B. Siaton, Benjamin J. Smith, A. V. Van Voorhees, A. Jonsson, A. A. Shah, Nancy M. Sullivan, Marat Turgunbaev, Laura C Coates, A. Gottlieb, M. Magrey, W. B. Nowell, A. Orbai, Soumya M. Reddy, J. Scher, E. Siegel, M. Siegel, Jessica A Walsh, Amy S. Turner, J. Reston   +35 more
semanticscholar   +1 more source

Treatment guidelines in psoriatic arthritis

Rheumatology, 2020
Psoriatic arthritis (PsA) is a complex inflammatory musculoskeletal and skin disease. The treatment of PsA has changed substantially over the past 10 years.
A. Ogdie, L. Coates, D. Gladman
semanticscholar   +1 more source

Psoriasis Area and Severity Index response in moderate-severe psoriatic patients switched to adalimumab: results from the OPPSA study [PDF]

, 2018
Background: Few studies have compared the efficacy of switching to adalimumab in the real-life setting in plaque psoriasis patients. Objective: To evaluate the effect of adalimumab in psoriasis patients previously treated with other biologics.
Armesto, Burmester, Carrera, Davison, Edson-Heredia, Elm, Gisondi, Gisondi, Gisondi, Gordon, Gossec, Gossec, Gottlieb, Griffiths, Gupta, Honda, Kurd, Lernia, Lernia, López-Ferrer, Lümig, Menter, Menter, Menter, Mrowietz, Nestle, Ortonne, Papoutsaki, Papp, Papp, Papp, Papp, Salvarani, Sbidian, Simone, Strober, Talamonti, Talamonti, Talamonti, Vandenbroucke, Vollenhoven   +40 more
core   +1 more source

Polyfunctional, Proinflammatory, Tissue‐Resident Memory Phenotype and Function of Synovial Interleukin‐17A+CD8+ T Cells in Psoriatic Arthritis

Arthritis & Rheumatology, 2020
Genetic associations imply a role for CD8+ T cells and the interleukin‐23 (IL‐23)/IL‐17 axis in psoriatic arthritis (PsA) and other spondyloarthritides (SpA). IL‐17A+CD8+ (Tc17) T cells are enriched in the synovial fluid (SF) of patients with PsA, and IL‐
K. Steel, U. Srenathan, M. Ridley, Lucy E. Durham, Shih-Ying Wu, Sarah Ryan, C. Hughes, E. Chan, B. Kirkham, L. Taams   +9 more
semanticscholar   +1 more source

Secukinumab sustains improvement in signs and symptoms of psoriatic arthritis: 2 year results from the phase 3 FUTURE 2 study [PDF]

, 2017
Objectives. To assess long-term efficacy, safety and tolerability of secukinumab up to 104 weeks in patients with active PsA. Methods. Patients with PsA (n = 397) were randomized to s.c. secukinumab 300, 150 or 75 mg or placebo at baseline, weeks 1, 2,
Delicha, Eumorphia-Maria, Gottlieb, Alice B., Kajekar, Radhika, Kirkham, Bruce, McInnes, Iain B., Mease, Philip J., Mpofu, Shephard, Pricop, Luminita, Rahman, Proton, Ritchlin, Christopher T.   +9 more
core   +2 more sources

Tumor necrosis factor inhibitors in psoriatic arthritis. [PDF]

, 2017
INTRODUCTION: Psoriatic arthritis (PsA) is a chronic inflammatory disease that can result in significant disability. With the emergence of tumor necrosis factor inhibitors (TNFi), therapeutic outcomes in PsA have improved substantially.
Kraft, Walter K., Mantravadi, Santhi, Ogdie, Alexis   +2 more
core   +2 more sources

Efficacy and safety of secukinumab administration by autoinjector in patients with psoriatic arthritis: results from a randomized, placebo-controlled trial (FUTURE 3) [PDF]

, 2018
Background: The study aimed to assess 52-week efficacy and safety of secukinumab self-administration by autoinjector in patients with active psoriatic arthritis (PsA) in the FUTURE 3 study (ClinicalTrials.gov NCT01989468).
Andersson, Mats, Blanco, Ricardo, Dokoupilova, Eva, FUTURE 3 study group, Kajekar, Radhika, McInnes, Iain B, Mease, Philip J, Mpofu, Shephard, Nash, Peter, Pricop, Luminita, Rahman, Proton, Ritchlin, Christopher T   +11 more
core   +1 more source